AVISE CTD Patient Information
The one thing that is worse than suffering painful and confusing symptoms is the uncertainty from not knowing the cause of the illness. Systemic Lupus Erythematosus (SLE) is among the most complex diagnoses to make due to variety of symptoms and the many illnesses that are lupus-like.
About AVISE® CTD
AVISE® CTD is intended to help everyone achieve the dignity of a diagnosis so that appropriate treatment can occur. If you or a loved one are concerned about the possibility of having lupus, our test is designed to help you work with your physician to achieve the dignity of a diagnosis.
A test called ANA (antinuclear antibodies) is the most common screening test when there is suspicion of an autoimmune disease like SLE, however that is just a starting point. When a test result returns positive for ANA, that does not mean a person has an autoimmune disease and in fact it is estimated that 13% of healthy Americans test positive for ANA*.
|When SLE is suspected due to a history of “lupus-like” symptoms and or a positive ANA test result, then it becomes important for your physician to order detailed clinical laboratory testing to seek prompt answers. AVISE® CTD is a comprehensive panel that leverages the highest quality standards and scientific analysis to accurately inform your physician’s diagnosis. Some clinically validated tests called Cell-bound Complement Activation Products (CB-CAPs) are only available through the AVISE® test and can improve the accuracy of the results.|
Adapted from Ogelsby et al. Apple Health Econ Health Policy (2014) 12:179-190
Take the next step
If you are ready to find out what the underlying reasons are for your symptoms then talk to your doctor about the AVISE® CTD diagnostic test. With over 90,000 tests performed, there are many doctors familiar with AVISE® CTD, however, you can open and print a physician communication letter below to help explain the test in greater detail in case your physician is not familiar with this novel service.
*Satoh M, et al. Prevalence and Sociodemographic Correlates of Antinuclear Antibodies in the United States. Arthritis & Rheumatism. Vol. 64, No. 7, July 2012, pp 2319–2327. DOI 10.1002/art.34380